Welcome to the Adenosine-Pathway Targeted Cancer Immunotherapy Summit
The inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit is the only meeting dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need.
As recent clinical trial announcements create a surge of reinvigorated confidence in the field, join 80+ industry and academic thought leaders to analyze the latest developments in understanding adenosine signaling in the TME, rationalize drug combinations to enhance patient responses, and explore tools that quantify adenosine to select the patient.
Explore how to leverage biomarkers to evaluate disease, identify patient responders, and monitor treatment to enhance patient outcomes with iTeos Therapeutics
Hear from leading industry professionals on their selected combination of treatments that enhance potency and efficacy of these targeted therapies with Astrazeneca and Corvus Pharmaceuticals
Analyze the optimum target point in the pathway and understand the role of adenosine signaling in the context of the hypoxic TME with Harvard Medical School, Northeastern University and Aurigene
Assess the rationale of Phanes Therapeutics' preclinical model and uncover the initial challenges that experts have overcome
Discuss which cancers are addicted to adenosine and how to progress adenosine-pathway therapies to the patient with leading experts including Domain Therapeutics and Takeda
Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.